Form 8-K - Current report:
SEC Accession No. 0001193125-26-316929
Filing Date
2026-07-27
Accepted
2026-07-27 08:05:07
Documents
11
Period of Report
2026-07-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d30807d8k.htm   iXBRL 8-K 24996
  Complete submission text file 0001193125-26-316929.txt   139395

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20260724.xsd EX-101.SCH 3162
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20260724_lab.xml EX-101.LAB 17992
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20260724_pre.xml EX-101.PRE 11249
14 EXTRACTED XBRL INSTANCE DOCUMENT d30807d8k_htm.xml XML 3653
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 261202881
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)